Free Trial
NASDAQ:SLDB

Solid Biosciences Q2 2025 Earnings Report

Solid Biosciences logo
$6.29 +0.10 (+1.62%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$6.27 -0.02 (-0.32%)
As of 08/8/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.51
Beat/Miss
N/A
One Year Ago EPS
N/A

Solid Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Solid Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Solid Biosciences Earnings Headlines

Solid Bio Green on Fast Track Nod
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
SLDB - Solid Biosciences Inc Executives - Morningstar
See More Solid Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email.

About Solid Biosciences

Solid Biosciences (NASDAQ:SLDB), a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

View Solid Biosciences Profile

More Earnings Resources from MarketBeat